


REGISTERED NUMBER: 09470532 (England and Wales)

REPORT OF THE DIRECTORS AND  
UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2020  
FOR  
RENABLE PHARMA LTD



CONTENTS OF THE FINANCIAL STATEMENTS  
for the Year Ended 31 DECEMBER 2020

	Page
Company Information	1
Report of the Directors	2
Income Statement	3
Balance Sheet	4
Notes to the Financial Statements	5
Detailed Profit and Loss Account	6

RENABLE PHARMA LTD  
COMPANY INFORMATION  
for the Year Ended 31 DECEMBER 2020

**DIRECTORS:**

Duncan James Reeves  
Glen Edward Curran  
Paul Johnson

**REGISTERED OFFICE:**

Ground Floor  
Marlow International Parkway  
Marlow  
Buckinghamshire  
SL7 1YL

**REGISTERED NUMBER:**

09470532 (England and Wales)

REPORT OF THE DIRECTORS  
for the Year Ended 31 DECEMBER 2020

The directors present their report with the financial statements of the company for the year ended 31 December 2020

**DIRECTORS**

The directors who have held office during the period from 1 January 2020 to the date of this report are as follows:

Duncan James Reeves


Glen Edward Curran

Paul Johnson

Nancy Ghattas (appointed August 3, 2019, resigned May 28, 2020)

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

**ON BEHALF OF THE BOARD:**

A handwritten signature in black ink, appearing to read 'D.J. Reeves', is written over a dotted line.

Duncan James Reeves - Director

Date: 22 September 2021

**INCOME STATEMENT**  
for the Year Ended 31 DECEMBER 2020

Notes	31/12/20 £	31/12/19 £
<b>TURNOVER</b>	-	-
	<hr/>	<hr/>
<b>OPERATING PROFIT and PROFIT BEFORE TAXATION</b>	-	-
Tax on profit	-	-
	<hr/>	<hr/>
<b>PROFIT FOR THE FINANCIAL YEAR</b>	-	-
	<hr/>	<hr/>

The notes form part of these financial statements

BALANCE SHEET  
31 DECEMBER 2020

	Notes	31/12/20 £	31/12/19 £
<b>CURRENT ASSETS</b>			
Debtors	2	1	1
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		1	1
<b>CAPITAL AND RESERVES</b>			
Called up share capital		1	1
<b>SHAREHOLDERS' FUNDS</b>		1	1

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.


The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In 25 June 2019, Allergan plc announced that it entered into a transaction agreement under which AbbVie Inc., a global research driven biopharmaceutical Company would acquire Allergan plc in a stock and cash transaction (the "AbbVie transaction") for a transaction equity value of US\$63 billion. On 14 October 2019, Allergan plc shareholders voted to approve the AbbVie transaction. The AbbVie transaction closed on the 8th May 2020. While the impact of the transaction is currently being evaluated, there is no anticipated impact to the current financial statements. AbbVie Inc is now the company's ultimate parent company.

The financial statements were approved by the Board of Directors on 14 September 2021 and were signed on its behalf by:

.....  


Duncan James Reeves – Director

NOTES TO THE FINANCIAL STATEMENTS  
for the Year Ended 31 DECEMBER 2020

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Financial instruments**

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered.

Basic financial liabilities

Basic financial liabilities, including creditors, and loans from fellow group companies are initially recognised at transaction price.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are initially recognised at transaction price.

**2. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31/12/20	31/12/19
	£	£
Other debtors	1	1
	<u>          </u>	<u>          </u>

DETAILED PROFIT AND LOSS ACCOUNT  
for the Year Ended 31 DECEMBER 2020

	31/12/20 £	31/12/19 £
<b>Income</b>	-	-
	<hr/>	<hr/>
<b>NET PROFIT</b>	-	-
	<hr/> <hr/>	<hr/> <hr/>